Aridis Pharmaceuticals (NASDAQ:ARDS) Trading 12.7% Higher

Shares of Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) rose 12.7% on Tuesday . The stock traded as high as $0.20 and last traded at $0.20. Approximately 782,286 shares traded hands during trading, a decline of 37% from the average daily volume of 1,248,948 shares. The stock had previously closed at $0.18.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price target on shares of Aridis Pharmaceuticals from $19.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, January 26th.

Aridis Pharmaceuticals Stock Up 12.7 %

The stock’s 50-day simple moving average is $0.32 and its 200 day simple moving average is $0.71. The company has a market cap of $6.02 million, a price-to-earnings ratio of -0.09 and a beta of 0.98.

Institutional Trading of Aridis Pharmaceuticals

Several hedge funds have recently made changes to their positions in ARDS. Armistice Capital LLC acquired a new stake in shares of Aridis Pharmaceuticals during the fourth quarter worth about $2,440,000. EP Wealth Advisors LLC purchased a new position in Aridis Pharmaceuticals in the third quarter valued at approximately $47,000. Group One Trading L.P. acquired a new stake in shares of Aridis Pharmaceuticals in the first quarter valued at approximately $48,000. Vanguard Group Inc. boosted its holdings in shares of Aridis Pharmaceuticals by 3.3% in the first quarter. Vanguard Group Inc. now owns 524,122 shares of the company’s stock valued at $922,000 after acquiring an additional 16,785 shares during the period. Finally, State Street Corp boosted its holdings in shares of Aridis Pharmaceuticals by 54.2% in the third quarter. State Street Corp now owns 43,247 shares of the company’s stock valued at $40,000 after acquiring an additional 15,200 shares during the period. Institutional investors and hedge funds own 10.89% of the company’s stock.

Aridis Pharmaceuticals Company Profile

(Get Rating)

Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J.